Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the landscape of oncology, offering personalized cellular solutions for hematologic malignancies and expanding into solid tumors and autoimmune disorders. By engineering a patient’s own T-cells to recognize and destroy cancer cells, CAR-T therapies provide unprecedented efficacy, often in patient populations with limited treatment options.
The global CAR-T market has grown substantially in recent years, climbing to 13 approvals worldwide. Seven of these therapies have been approved by the U.S. FDA, with subsequent approvals in other major healthcare markets. These therapies include Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Aucatzyl. Beyond the U.S., four CAR-T therapies (Relma-cel, Fucaso, Yuanruida, and Zever-cel) have been approved by China’s National Medical Products Administration (NMPA), while two therapies, NexCAR19 and Qartemi, have received approval from India’s Central Drugs Standard Control Organisation (CDSCO). [Read more…]
